表紙
市場調查報告書

關注市場分析:化療誘發性貧血

Market Spotlight: Chemotherapy-Induced Anemia

出版商 Datamonitor Healthcare 商品編碼 917496
出版日期 內容資訊 英文 32 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
關注市場分析:化療誘發性貧血 Market Spotlight: Chemotherapy-Induced Anemia
出版日期: 2019年11月15日內容資訊: 英文 32 Pages
簡介

本報告提供化療誘發性貧血的治療藥市場相關分析,疾病概要和患者數的變化、預測,目前主要的治療方法,法規環境和近幾年主要的事件,現在開發中臨床實驗的進展上市計劃,主要的治療藥的市場趨勢預測,資本交易的動向等調查。

概要

要點

疾病的背景情況

  • 定義
  • 患者亞型
  • 症狀
  • 風險因素
  • 診斷

治療方法

  • 鐵補充品
  • 輸血
  • 促血紅細胞生長素刺激劑 (ESA)

流行病學

已上市醫藥品

開發平台藥物

不久將來的活動

法規相關的主要活動

成功的可能性

授權合約、資產收購交易

商機

臨床實驗形勢

  • 贊助商數:各狀態
  • 贊助商數:各階段 (相位)

參考資料

  • 處方藥的資訊

附錄

目錄
Product Code: DMKC0206134

This Market Spotlight report covers the chemotherapy-induced anemia market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

Chemotherapy-induced anemia (CIA) is a common complication in cancer patients receiving chemotherapy. The proportions of CIA and the severity of anemia vary by region, cancer type, and stage.

All of the approved drugs for CIA target the erythropoietin receptor. These drugs are all administered via both the intravenous and subcutaneous routes.

There are only two industry-sponsored drugs in active clinical development for CIA, both of which are in Phase III. Therapies in development for CIA focus on targets such as iron and hypoxia-inducible factor-prolyl hydroxylase (HIF-PH). These drugs are administered via the intravenous and oral routes.

The only high-impact upcoming event in the CIA space is topline Phase III trial results for roxadustat. The overall likelihood of approval of a Phase I marrow or peripheral blood stimulator asset is 18.9%, and the average probability a drug advances from Phase III is 66.7%. Drugs, on average, take 9.0 years from Phase I to approval, compared to 9.3 years in the overall hematology space.

There have been only two licensing and asset acquisition deals involving CIA drugs during 2014-19. The values of the deals have not been disclosed.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for CIA have been in the late phases of development, with 61% of trials in Phase III-IV, and 39% in Phase I-II.

Clinical trial activity in the CIA space is dominated by completed trials. Amgen has the highest number of completed clinical trials for CIA, with 67 trials.

Amgen leads industry sponsors with the highest number of clinical trials for CIA, followed by Johnson & Johnson.

TABLE OF CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Disease definition
  • Patient subtypes
  • Symptoms
  • Risk factors
  • Diagnosis

TREATMENT

  • Iron supplements
  • Blood transfusion
  • Erythropoietin-stimulating agents (ESAs)

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Pfizer's Epogen Biosimilar Retacrit Launches At 33% Off In A US Market Where Amgen's Already Competitive

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Overview of pipeline drugs for CIA in the US
  • Figure 2: Pipeline drugs for CIA, by company
  • Figure 3: Pipeline drugs for CIA, by drug type
  • Figure 4: Pipeline drugs for CIA, by classification
  • Figure 5: Key upcoming events in CIA
  • Figure 6: Probability of success in the CIA pipeline
  • Figure 7: Licensing and asset acquisition deals in CIA, 2014-19
  • Figure 8: Clinical trials in CIA
  • Figure 9: Top 10 drugs for clinical trials in CIA
  • Figure 10: Top 10 companies for clinical trials in CIA
  • Figure 11: CIA trials status
  • Figure 12: CIA trials sponsors, by phase

LIST OF TABLES

  • Table 1: Chemotherapy-treated patients with CIA, by grade, in the US
  • Table 2: Marketed drugs for CIA
  • Table 3: Pipeline drugs for CIA in the US
  • Table 4: Historical global sales, by drug ($m), 2014-18
  • Table 5: Forecasted global sales, by drug ($m), 2019-23
Back to Top